As the liver and thyroid are closely associated with thyroid hormone, its important role in de novo lipogenesis (DNL), beta-oxidation (FAO), cholesterol metabolism and carbohydrate metabolism has led to a number of animal studies and clinical trials investigating TH analogues and TR agonists as potential therapies for NAFLD and hyperlipidemia (8). Here, TG is linked to metabolic dysfunction-associated steatotic liver disease.